HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gillette women's shaving systems $1 bil. sales mark predicted by 2001.

This article was originally published in The Rose Sheet

Executive Summary

GILLETTE $1 BIL. MARK IN SALES TO WOMEN PREDICTED BY 2001, with sales from the firm's women's wet shave systems expected to triple in the "next several years, exceeding" $750 mil., President and Chief Operating Officer Michael Hawley told shareholders at the firm's annual meeting in Boston April 16. Wet shave systems, combined with sales from the firm's disposable razor business, including the new Agility disposables, should help annual sales from women's blades and razors "approach $1 bil.," Hawley said. Worldwide "expansion of female shaving is another major avenue for profitable growth," Hawley stated, noting that Sensor for Women and SensorExcel for Women have achieved substantial sales increases in the North Atlantic and International Group markets.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel